Global Montelukast Sodium Intermediate MK-5 Market Strategic Research Report

Scope of the Report

The global Montelukast Sodium Intermediate MK-5 market size is predicted to grow from US$ 31.90 million in 2025 to US$ 45.54 million in 2032; it is expected to grow at a CAGR of 5.2% from 2026 to 2032.

Montelukast Sodium Intermediate MK-5 (CAS 142569-70-8) is a key chiral advanced intermediate used in the synthesis of Montelukast Sodium API. It is commonly identified as (S,E)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propan-1-ol, with molecular formula C29H28ClNO2 and molecular weight of approximately 457.99. Key quality attributes include assay, chiral purity, related substances, moisture, and residual solvents, all of which directly affect downstream API yield, impurity profile, and regulatory compliance. Based on an integrated assessment of industry supply, trade flows, and downstream API demand, global Montelukast Sodium Intermediate MK-5 production in 2025 is estimated at approximately 195 metric tons.

Montelukast Sodium is a mature, large-volume global generic API, and continuing demand for asthma and allergic-rhinitis therapies provides a stable consumption base for MK-5. As a late-stage chiral intermediate close to the API step, MK-5 carries substantially higher unit value than early-stage commodity intermediates. Downstream buyers therefore emphasize batch consistency, chiral purity, impurity control, and supply reliability rather than price alone.

India is one of the most important demand and processing hubs for MK-5. Indian manufacturers such as Aarti Pharmalabs, Ceyone Life Sciences, BEC Chemicals, and Kopalle Pharma Chemicals have Montelukast-intermediate manufacturing capabilities, while major Indian API producers continue to import CAS 142569-70-8 from China. Trade records in 2024–2025 show imports by companies including Morepen Laboratories, Hetero Drugs, Honour Lab, Dhanuka Laboratories, and Melody Healthcare, indicating a dual market structure in which strong domestic manufacturing coexists with imported supply for cost, quality, or capacity reasons.

Future competition will center on high-ee chiral control, low-impurity processes, robust scale-up, EHS compliance, and cost optimization. Ongoing supply-chain localization by Indian API manufacturers should create substitution opportunities for domestic MK-5 producers, while established Chinese suppliers are likely to remain important in the Indian import market due to mature processes and scale economics.

This report presents a comprehensive overview of the global Montelukast Sodium Intermediate MK-5 market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 98.0%–<99.0%
• 99.0%–<99.5%
• ≥99.5%

Segment by Chiral Purity

• 98.0%–<99.0% ee
• 99.0%–<99.5% ee
• ≥99.5% ee
• Other Chiral Purity Grades

Segment by Physical Form

• Crystalline/Powder Form
• Amorphous/Foam Form
• Other Physical Forms

Segment by Application

• Commercial Montelukast Sodium API Manufacturing
• Pilot & Validation Batch Manufacturing
• Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Montelukast Sodium Intermediate MK-5 market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Commercial Montelukast Sodium API Manufacturing, Pilot & Validation Batch Manufacturing, Other evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact